{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:04:15Z","timestamp":1771927455990,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neoantigens from the Kirsten rat sarcoma viral oncogene homolog (KRAS) are specific cancer therapeutic targets. However, to date, no immune product targeting KRAS neoantigens has been approved for clinical use, and key challenges regarding efficacy and generalizability remain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we isolated a natural human T-cell antigen receptor (TCR) 0 that specifically recognized human leukocyte antigen (HLA)-A*11:01+ T2 cells pulsed with KRAS G12V\n                      <jats:sub>8\u201316<\/jats:sub>\n                      peptides. However, TCR0 gene-transduced T\u00a0cells\u00a0demonstrated inadequate response to tumor cell lines. We generated T cells expressing a TCR0 mutant, being designated as TCR3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TCR3-T cells showed significantly optimized avidity and response to tumor cell lines, retained specificity for the KRAS G12V8\u201316 peptide with no response to normal cells, killed tumor cells that highly expressed programmed cell death-ligand 1\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      , proliferated without being seriously affected by indoleamine 2,3-dioxygenase, resisted transforming growth factor \u03b2, and infiltrated and recruited other immune cells to the tumor site through chemokines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>TCR3 may be useful for KRAS neoantigen-targeted clinical immunotherapy, help resolve cancer immune escape, and enhance clinical effectiveness and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1736294","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:47Z","timestamp":1769411987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Avidity-optimized TCR-T cells target KRAS neoantigens for potent cancer clearance and tumor microenvironment remodeling"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhaoduan","family":"Liang","sequence":"first","affiliation":[{"name":"Bioland Laboratory","place":["Guangzhou, Guangdong, China"]},{"name":"Guangzhou Regenerative Medicine and Health GuangDong Laboratory","place":["Guangzhou, Guangdong, China"]},{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqiong","family":"Guan","sequence":"additional","affiliation":[{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingling","family":"Wu","sequence":"additional","affiliation":[{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxuan","family":"Cai","sequence":"additional","affiliation":[{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Bioland Laboratory","place":["Guangzhou, Guangdong, China"]},{"name":"Guangzhou Regenerative Medicine and Health GuangDong Laboratory","place":["Guangzhou, Guangdong, China"]},{"name":"T-cell Immunity Optimized Cure (TIOC) Therapeutics Limited","place":["Zhongshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"02","DOI":"10.3390\/cancers12051286","article-title":"Spectrum of germline BRCA1 and BRCA2 variants identified in 2351 ovarian and breast cancer patients referring to a reference cancer hospital of Rome","volume":"12","author":"Santonocito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921964117","article-title":"High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D","volume":"117","author":"Sim","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","article-title":"Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen","volume":"13","author":"Poole","year":"2022","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102309","article-title":"KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond","volume":"101","author":"Nagasaka","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1212","article-title":"Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations","volume":"30","author":"Linette","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223433","article-title":"Small molecular inhibitors for KRAS-mutant cancers","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1172\/JCI153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049007","article-title":"Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation","volume":"51","author":"Bassan","year":"2021","journal-title":"Eur J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7308","article-title":"Quantifying and imaging NY-ESO-1\/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors","volume":"176","author":"Purbhoo","year":"2006","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133883","article-title":"Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100084","article-title":"Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations","volume":"1","author":"Choi","year":"2021","journal-title":"Cell Rep Methods"},{"key":"B28","unstructured":""},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26840","article-title":"Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells","volume":"2","author":"Bossi","year":"2013","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2567.2011.03515.x","article-title":"Structural and biophysical determinants of alphabeta T-cell antigen recognition","volume":"135","author":"Bridgeman","year":"2012","journal-title":"Immunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1110\/ps.051936406","article-title":"Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity","volume":"15","author":"Dunn","year":"2006","journal-title":"Protein Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.080078297","article-title":"In vitro evolution of a T cell receptor with high affinity for peptide\/MHC","volume":"97","author":"Holler","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.cub.2021.03.094","article-title":"EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas","volume":"31","author":"Hill","year":"2021","journal-title":"Curr Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2022.08.004","article-title":"Immune cellular components and signaling pathways in the tumor microenvironment","volume":"86","author":"Yenyuwadee","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms242417536","article-title":"Insights into the tumor microenvironment-components, functions and therapeutics","volume":"24","author":"Baghy","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms21218412","article-title":"CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms22020843","article-title":"The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature","volume":"22","author":"Korbecki","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cac2.12010","article-title":"CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target","volume":"40","author":"Zhang","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.05.018","article-title":"GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells","volume":"42","author":"Helft","year":"2015","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:11:53Z","timestamp":1771924313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1736294"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1736294","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1736294"}}